EP157: Major Improvements in Oncology Outcomes When Patients Self-Report Symptoms, with Ethan Basch, Oncologist and Director of Cancer Outcomes Research at University of North Carolina at Chapel Hill
Relentless Health Value™October 17, 201733:0145.34 MB

EP157: Major Improvements in Oncology Outcomes When Patients Self-Report Symptoms, with Ethan Basch, Oncologist and Director of Cancer Outcomes Research at University of North Carolina at Chapel Hill

Ethan Basch, MD talks today about a randomized clinical trial where 766 patients used a web-based system to self-report symptoms, triggering alerts to clinicians. The results were impressive. There are learnings and inspiration in this episode for anyone pursuing better patient outcomes, with special relevance for organizations rolling with a value-based care model.

Dr. Ethan Basch is an oncologist and Director of Cancer Outcomes Research at the University of North Carolina.  His research group established that up to half of patients’ symptom side effects go undetected during cancer treatment and clinical trials, and that patient engagement and questionnaires substantially improve detection. His team determined that integrating web-based patient-reported symptoms into oncology clinical practice improves clinical outcomes and reduces health service utilization. His team created a system for the National Cancer Institute (NCI) to collect patient-reported side effects during cancer trials called the ‘PRO-CTCAE.’ Dr. Basch is also involved in efforts to bring PROs into comparative effectiveness research, routine care, and quality improvement. He is a member of the U.S. National Cancer Institute’s Board of Scientific Advisors, PCORI’s Methodology Committee, and is an Associate Editor at JAMA. 

Dr. Basch will discuss results of a widely cited randomized controlled trial testing a “PRO intervention” in routine cancer care, that was a Plenary session at the ASCO annual cancer meeting and was published in JAMA earlier this year.  In this trial, 766 patients receiving routine outpatient chemotherapy for metastatic solid tumors were randomly assigned to self-report 12 common symptoms via the web, or to usual care. Treating physicians received symptom printouts at visits and nurses received email alerts when participants reported severe or worsening symptoms. Overall survival was tabulated based on medical records and Social Security Death Index data, estimated using the Kaplan-Meier method, and compared between arms using a log-rank test and Cox proportional hazards regression adjusting for age, sex, race, education level, and cancer type.  Cancer types included genitourinary (32% of patients), gynecologic (23%), breast (19%), and lung cancer (26%).  Survival results were assessed after a median follow up of 7 years and 517/766 (67%) of participants had died.  Median overall survival in the PRO intervention arm was 5.2 months longer than the control arm (31.2 vs. 26.0 months, p=0.03).  These results demonstrate that systematic symptom monitoring during outpatient chemotherapy using web-based patient-reported outcomes confers overall survival benefits.  These results are being further explored in a U.S. national implementation trial.


00:00 Ethan talks his work on a self-reporting symptom system.
02:20 The results of the self-reporting system trial.
03:00 Does using a self-reporting symptom system improve Clinical Outcomes?
04:30 Analyzing the data from this self-reporting system.
09:45 The improvements in Quality of Life this self-reporting study found.
10:20 The decrease in ER visits with self-reporting symptoms.
10:45 The extension of chemotherapy treatments self-reporting patients were able to achieve.
12:50 What inspired Ethan to take this sort of a project on.
13:15 The opportunity to improve the ability to detect patient symptoms.
15:30 Refining study techniques and approaches for successful trials.
19:20 Onboarding patients for studies.
24:15 Implementing the study from the Clinician side.
26:20 The requirements needed for onboarding staff onto a successfully implemented study.
29:45 The relevance to Value-Based Reimbursement.
31:00 The tangible impacts of catching symptoms early that increased the survival benefit of patient-reporting.
34:00 EP131, relevant insight from Zach Silverzweig of Cipherhealth.
36:00 A better way to monitor how patients are doing and improve the quality of care.
37:20 You can learn more about the study in the Journal of the American Medical Association & the Journal of Clinical Oncology.

care,digital,health,healthcare,marketing,tech,university of north carolina at chapel hill,oncology,

Recent Episodes

Encore! EP397: The Minefield That Is a PBM Contract and Also Some Advice for EBCs Who Are Taking Money Under the Table, With Paul Holmes
July 18, 202434:1531.35 MB

Encore! EP397: The Minefield That Is a PBM Contract and Also Some Advice for EBCs Who Are Taking Money Under the Table, With Paul Holmes

Today is an encore because I am going on vacation next week. It always feels a little bit like a time warp because by the time this show will air, I will be back from vacation. This show with Paul Holmes was one of the most popular episodes of 2023 and definitely is just as relevant now. A lot of t...

EP444: Two State Healthcare Laws Often Don’t Go as Planned: CON and COPA, With Ann Kempski
July 11, 2024
444
35:1932.33 MB

EP444: Two State Healthcare Laws Often Don’t Go as Planned: CON and COPA, With Ann Kempski

Unintended consequences is a thing. ERCowboy wrote on Twitter a while back, “In any complex system, the likelihood of unintended consequences vastly outweighs the predictability of intended ones.” In this healthcare podcast, we’re talking about two state laws where this is apropos: CON (Certificate...

EP443: Let Us Never Pay the First Bill in Honor of Marshall Allen
July 04, 2024
443
36:1733.21 MB

EP443: Let Us Never Pay the First Bill in Honor of Marshall Allen

The first time I figuratively, not actually, met Marshall Allen was the day he did not meet Dave Chase for lunch. Dave was in Manhattan, and he was supposed to meet up with Marshall. But something happened, and Marshall was unable to make said lunch. So, I filled in for Marshall, who I had never me...

EP442: A Short Rumination on Saving Money, Except Not Saving Money. Oncology Side Effect Management as a Case Study, With Andreas Mang
June 27, 2024
442
18:5117.25 MB

EP442: A Short Rumination on Saving Money, Except Not Saving Money. Oncology Side Effect Management as a Case Study, With Andreas Mang

This week, I’m gonna play an outtake, I guess it could be called, from the show with Andreas Mang from Blackstone that we wound up cutting for reasons of time and topic; but it’s been on my mind ever since. So, here’s this clip; and then I’m gonna invite you to partake in my ruminations because the...

EP441: Tables Get Turned. This Is Me Interviewed by Abby Burns From Radio Advisory About What Is Value
June 20, 2024
441
40:3037.08 MB

EP441: Tables Get Turned. This Is Me Interviewed by Abby Burns From Radio Advisory About What Is Value

The show today is a recording of an earlier conversation between Abby Burns and myself. This original conversation happened during the Raising the Value Bar Summit, which was a summit all about value and the what, why, and how of it all. For a full transcript of this episode, click here . If you en...

EP440: What Is the Optimal Size for a Medical Practice? With David Muhlestein, PhD, JD
June 13, 2024
440
38:1535.01 MB

EP440: What Is the Optimal Size for a Medical Practice? With David Muhlestein, PhD, JD

Well, I reached out to David Muhlestein, PhD, JD, the other day to find out what he was up to since he left Leavitt Partners, which had been acquired by HMA, Health Management Associates. Answer: He’s building his own company in stealth mode. Stay tuned. For a full transcript of this episode, click...

EP439: Fixing the Generic Drug Pricing Problem, Where Patients Pay More When They Use Their Insurance, With Luke Slindee, PharmD
June 06, 2024
439
28:5639.74 MB

EP439: Fixing the Generic Drug Pricing Problem, Where Patients Pay More When They Use Their Insurance, With Luke Slindee, PharmD

In the Ge Bai show ( EP420 ), one solve was offered for helping patients pay the lowest possible price for generic drugs. In this healthcare podcast, Luke Slindee, PharmD, offers another solve. That’s where this conversation is going, but now let’s start from the beginning. For a full transcript of...

Listen and Follow

Sponsored by Aventria Health Group
©2024 BD Bridges LLC. All Rights Reserved.